Additional file 1 of Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands
Creators: name: de Boer, Pieter T.
name: van Werkhoven, Cornelis H.
name: van Hoek, Albert Jan
name: Knol, Mirjam J.
name: Sanders, Elisabeth A. M.
name: Wallinga, Jacco
name: de Melker, Hester E.
name: Steens, Anneke
Publisher: name: figshare
Year: 2024
Subjects: subject: Medicine
subject: Microbiology
subject: FOS: Biological sciences
subject: Pharmacology
subject: Geology
subject: FOS: Earth and related environmental sciences
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences

description: Additional file 1: Supplementary introduction: Table S1. Summary of previous studies on the cost-effectiveness PCV15, PCV20 and PCV21 in adults. Supplementary Methods: Figure S1. Schematic overview of the model. Figure S2. The annual incidence of IPD cases in the Netherlands among adults aged ≥60 years per 100,000 inhabitants over the period 2004-2019 by serotype category. Figure S3. Fitted vaccine effectiveness of PPV23 against vaccine-type IPD and vaccine-type hospitalized NIPP at time of vaccination, across different vaccination ages. Figure S4. Fitted vaccine efficacy of PCVs against vaccine-type IPD and vaccine-type hospitalized NIPP at time of vaccination, across different vaccination ages. Figure S5. The number of QALYs lost by age of death. Table S2. Epidemiological parameter values. Table S3. Serotype categories distinguished and serotype distribution from IPD cases aged 60+ years in the Netherlands in 2019. Table S4. Parameter values of costs. Table S5. Parameter values of quality-adjusted life years (QALYs). Table S6. Parameters varied in the one-way sensitivity analyses and their input values. Supplementary Results: Figure S6. One-way sensitivity analysis of the cost-effectiveness of different pneumococcal vaccination strategies in a 65-years-old cohort while continuing PCV10 in children, or with a switch to PCV13, PCV15 or PCV20. Figure S7. Cost-effectiveness of various vaccination pneumococcal vaccination strategies compared to no vaccination by vaccination age, while PCV10 is continued in children. Figure S8. Cost-effectiveness of different pneumococcal vaccination strategies in older adults for different vaccination ages in the age-range 60 to 85 years, while varying the childhood vaccine between PCV10, PCV13, PCV15, and PCV20. Table S7. Clinical impact, number needed to vaccinate and cost-effectiveness of different pneumococcal vaccination strategies compared to no vaccination in a 65-year-old cohort, while continuing PCV10 in children. Table S8. Clinical impact, number needed to vaccinate and cost-effectiveness of different pneumococcal vaccination strategies compared to no vaccination in a 65-year-old cohort, while switching to PCV13 in children. Table S9. Clinical impact, number needed to vaccinate and cost-effectiveness of different pneumococcal vaccination strategies compared to no vaccination in a 65-year-old cohort, while switching to PCV15 in children. Table S10. Clinical impact, number needed to vaccinate and cost-effectiveness of different pneumococcal vaccination strategies compared to no vaccination in a 65-year-old cohort, while switching to PCV20 in children. Table S11. QALY losses, costs and incremental cost-effectiveness ratio of different vaccination strategies in a 65-year-olds cohort, while continuing PCV10 in children. Table S12. Incremental cost-effectiveness ratio of different vaccination strategies in a 65-year-olds cohort, while switching to PCV13 in children. Table S13. Incremental cost-effectiveness ratio of different vaccination strategies in a 65-year-olds cohort, while switching to PCV15 in children. Table S14. Incremental cost-effectiveness ratio of different vaccination strategies in a 65-year-olds cohort, while switching to PCV20 in children. Table S15. Clinical impact, number needed to vaccinate and cost-effectiveness of different pneumococcal vaccination strategies in a 60-year-old cohort, while PCV10 is continued in children. Table S16. Clinical impact, number needed to vaccinate and cost-effectiveness of different pneumococcal vaccination strategies in a 70-year-old cohort, while PCV10 is continued in children. Table S17. Clinical impact, number needed to vaccinate and cost-effectiveness of different pneumococcal vaccination strategies in a 75-year-old cohort, while PCV10 is continued in children. Table S18. Clinical impact, number needed to vaccinate and cost-effectiveness of different pneumococcal vaccination strategies in a 80-year-old cohort, while PCV10 is continued in children. Table S19. Clinical impact, number needed to vaccinate and cost-effectiveness of different pneumococcal vaccination strategies in a 85-year-old cohort, while PCV10 is continued in children. Table S20. Incremental cost-effectiveness ratio of different vaccination strategies in a 60-year-olds cohort, while remaining PC10 in children. Table S21. Incremental cost-effectiveness ratio of different vaccination strategies in a 70-year-olds cohort, while remaining PC10 in children. Table S22. Incremental cost-effectiveness ratio of different vaccination strategies in a 75-year-olds cohort, while remaining PC10 in children. Table S23. Incremental cost-effectiveness ratio of different vaccination strategies in a 80-year-olds cohort, while remaining PC10 in children. Table S24. Incremental cost-effectiveness ratio of different vaccination strategies in a 85-year-olds cohort, while remaining PC10 in children.